1-16 of 16
Habte Yimer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Yuliya Linhares, Cesar Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan Carlos Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Min Vedal, Connor Mailley, Ricardo Espinola, Bassam Mattar
Journal: Blood
Blood (2022) 140 (Supplement 1): 10416–10418.
https://doi.org/10.1182/blood-2022-159595
Published: 2022
Journal Articles

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Linlin Xu, Mazyar Shadman, Anusha Ponakala, Ian W. Flinn, Moshe Yair Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Aileen Cohen, Dih-Yih Chen, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9269–9271.
https://doi.org/10.1182/blood-2022-167758
Published: 2022
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Hun Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul Gandhi, John Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood (2022) 140 (Supplement 1): 763–765.
https://doi.org/10.1182/blood-2022-156553
Published: 2022
Journal Articles

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

Tapan M. Kadia, Christopher Benton, Harry P. Erba, Mitul Gandhi, Moshe Y. Levy, Mary-Elizabeth M. Percival, Matthew Ulrickson, Habte Yimer, Min Yu, Zi Chen, Jing Wang, Mingyu Li, Mohammad Ahmad, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2022) 140 (Supplement 1): 11659–11660.
https://doi.org/10.1182/blood-2022-162627
Published: 2022
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Hun Ju Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Matthew R. Peterson, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul D. Gandhi, John Renshaw, Amanda L. Gillespie-Twardy, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood (2021) 138 (Supplement 1): 2454.
https://doi.org/10.1182/blood-2021-147891
Published: 2021
Journal Articles

Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia

Sudhir Manda, Bertrand Anz, III, Christopher Benton, E. Randolph Broun, Habte Yimer, John Renshaw, George F. Geils, Jr., Jose Cruz, Suzanne Fanning, Jason Melear, Jeff P. Sharman, Kingston Kang, Anders Svensson, Madhavi Pai, William Donnellan
Journal: Blood
Blood (2021) 138 (Supplement 1): 1265.
https://doi.org/10.1182/blood-2021-144886
Published: 2021
Journal Articles

Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

Robert M. Rifkin, Stephen J. Noga, Saulius K. Girnius, Kimberly Bogard, Sudhir Manda, Habte Yimer, Presley Whidden, Ruemu E. Birhiray, Philip Twumasi-Ankrah, Yikun Guo, Rami Owera, Leon Bernal-Mizrachi, Roger Lyons
Journal: Blood
Blood (2021) 138 (Supplement 1): 2726.
https://doi.org/10.1182/blood-2021-150094
Published: 2021
Journal Articles

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Sagar Lonial, Stefano R. Tarantolo, Ralph V. Boccia, Habte Yimer, Moshe Y. Levy, Rafat Abonour, Meera Mohan, Vivek Roy, Jeremy T. Larsen, Saulius K. Girnius, Cara A. Rosenbaum, Omar Nadeem, Deborah Berg, Bo Chao, Allison J Berger, Akito Nakamura, Yuhong Zhang, Keli Song, Christine K. Ward, Igor Proscurshim, Shaji Kumar
Journal: Blood
Blood (2021) 138 (Supplement 1): 2742.
https://doi.org/10.1182/blood-2021-148385
Published: 2021
Journal Articles

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

John E. Godwin, Bassam Mattar, Michael Maris, Carlos Bachier, Don Stevens, Daanish Hoda, Juan C. Varela, Mohamad Cherry, Suzanne Fanning, James Essell, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ricardo Espinola, Connor Mailley, Ariel Avilion, Ken Ogasawara, San-San Ou, Paul Shaughnessy
Journal: Blood
Blood (2021) 138 (Supplement 1): 1762.
https://doi.org/10.1182/blood-2021-148792
Published: 2021
Journal Articles

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Seung Tae Lee, Antonio Pinto, Habte Yimer, Don Stevens, Wanda Knopinska Posluszny, Merrill Kingman Shum, Sudhir Manda, Merav Leiba, Miguel Canales, Maciej Kaźmierczak, Wojciech Jurczak, Anna Sureda, Xiwen Ma, Kai Li, Kimberly Ingalls, Tara Arriola, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Grzegorz S. Nowakowski
Journal: Blood
Blood (2021) 138 (Supplement 1): 1420.
https://doi.org/10.1182/blood-2021-150025
Published: 2021
Journal Articles

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Ryan Porter, John M. Burke, Jennifer L. Cultrera, Jamal Misleh, Syed F. Zafar, Benjamin Freeman, Subramanya S. Rao, Habte Yimer, Arvind Chaudhry, Mitul D. Gandhi, Troy H. Guthrie, Edwin Kingsley, Praveen K. Tumula, Sudhir Manda, Dih-Yih Chen, Aileen Cohen, Kunthel By, Linlin Xu, Ye Liu, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 1410.
https://doi.org/10.1182/blood-2021-148544
Published: 2021
Journal Articles

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Ian W. Flinn, David Andorsky, Jason Melear, Sudhir Manda, Bertrand Anz, III, Kathryn Kolibaba, Habte Yimer, John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas-Ohlmayer, Suman Kambhampati, Tamas Vizkelety, John Pesko, Brenda Chyla, Dingfeng Jiang, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3725.
https://doi.org/10.1182/blood-2021-147258
Published: 2021
Journal Articles

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, DO, MS, William Bensinger, MD, John M Burke, Mohit Narang, MD, Don Stevens, MD, Sriya W. Gunawardena, MD, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Robert M Rifkin, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 152.
https://doi.org/10.1182/blood-2018-152
Published: 2018
Journal Articles

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Jeffrey P. Sharman, MD, Habte Yimer, MD, Michael Boxer, MD, Nicholas Di Bella, Sunil Babu, Jia Li, PhD, Yong Mun, Peter Trask, Anthony Masaquel, MPH, PhD, Carolina M Reyes, PhD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 683.
https://doi.org/10.1182/blood.V130.Suppl_1.683.683
Published: 2017
Journal Articles

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, William I. Bensinger, MD, John M Burke, MD, Sriya Gunawardena, MD, Murphy Sean, Hollee Parros, Yana Lutska, Mohamed Darif, PhD, Anil Londhe, PhD, Ming Qi, Jon Ukropec, Thomas Lin, Robert M. Rifkin, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1839.
https://doi.org/10.1182/blood.V130.Suppl_1.1839.1839
Published: 2017
Journal Articles

A Possible Mechanism for Synergy in Transcriptional Activation between AML1 and PU.1: Exclusion of the Co-Repressor CBFA2T3 (ETO-2, MTG16).

Kristine Baraoidan, BSc, Vinzon Ibanez, MSc, Chetna Mittal, PhD, Habte Yimer, MD, Suman Chakraborty, PhD, Kisle Sinha, PhD, Steven Ackerman, PhD, Giuseppina Nucifora, PhD, Yogenthiran Saunthararajah, MD
Journal: Blood
Blood (2004) 104 (11): 3545.
https://doi.org/10.1182/blood.V104.11.3545.3545
Published: 2004